PT - JOURNAL ARTICLE AU - Alberto Cedro-Tanda AU - Laura Gómez-Romero AU - Nicolás Alcaraz AU - Guillermo de Anda-Jauregui AU - Fernando Peñaloza AU - Bernardo Moreno AU - Marco A. Escobar-Arrazola AU - Oscar A. Ramirez-Vega AU - Paulina Munguia-Garza AU - Francisco Garcia-Cardenes AU - Mireya Cisneros-Villanueva AU - Jose L. Moreno-Camacho AU - Jorge Rodriguez-Gallegos AU - Marco A. Luna-Ruiz Esparza AU - Miguel A. Fernández Rojas AU - Alfredo Mendoza-Vargas AU - Juan Pablo Reyes-Grajeda AU - Abraham Campos-Romero AU - Ofelia Angulo AU - Rosaura Ruiz AU - Claudia Sheinbaum AU - José Sifuentes-Osornio AU - David Kershenobich AU - Alfredo Hidalgo-Miranda AU - Luis A. Herrera TI - The evolutionary landscape of SARS-CoV-2 variant B.1.1.519 and its clinical impact in Mexico City AID - 10.1101/2021.09.07.21262911 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.07.21262911 4099 - http://medrxiv.org/content/early/2021/09/18/2021.09.07.21262911.short 4100 - http://medrxiv.org/content/early/2021/09/18/2021.09.07.21262911.full AB - The SARS-CoV-2 pandemic is one of the most concerning health problems around the globe. We report the emergence of SARS-CoV-2 variant B.1.1.519 in Mexico City. This variant represented up to 90% of sequenced cases in February 2021. It is characterized by three amino acid changes in the spike protein: T478K, P681H, and T732A. We report the effective reproduction number of B.1.1.519 and present evidence of its geographical origin based on phylogenetic analysis. We also studied its evolution via haplotype analysis and identified the most recurrent haplotypes. Finally, we studied the clinical impact of B.1.1.519: patients infected with variant B.1.1.519 showed a highly significant adjusted odds ratio (aOR) increase of 1.85 over non-B.1.1.519 patients for developing a severe/critical outcome (P = 0.000296, 1.33–2.6 95% CI) and a 2.35-fold increase for hospitalization (P = 0.005, 1.32–4.34 95% CI). The continuous monitoring of this and other variants will be required to control the ongoing pandemic as it evolves.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Secretaria de Educacion, Ciencia, Tecnologia e Innovacion de la Ciudad de Mexico (SECTEI).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Residual RNA positive samples were recovered and sequenced from routine SARS CoV-2 diagnostic and were processed following Standardized Guideline for Epidemiological and Laboratory surveillance of Viral Respiratory Disease. The study was approved by the ethics and research committees of the Instituto Nacional de Medicina Genomica (CEI/1479/20 and CEI 2020/21).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available on GISAID website https://www.gisaid.org/ https://www.gisaid.org/